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Within the Burkholderia cepacia complex (Bcc), B.
cenocepacia portends increased mortality compared
with other species. We investigated the impact of Bcc
infection on mortality and re-infection following lung
transplant (LT). Species designation for isolates from
Bcc-infected patients was determined using 16S rDNA
and recA gene analyses. Of 75 cystic fibrosis patients
undergoing LT from September 1992 to August 2002,
59 had no Bcc and 16 had Bcc (including 7 B. ceno-
cepacia) isolated in the year before LT. Of the latter,
87.5% had Bcc recovered after transplantation, and all
retained their pretransplant strains. Survival was 97%,
92%, 76% and 63% for noninfected patients; 89%, 89%,
67% and 56% for patients infected with Bcc species
other than B. cenocepacia; and 71%, 29%, 29% and
29% for patients with B. cenocepacia (p = 0.014) at
1 month, 1 year, 3 years and 5 years, respectively. Pa-
tients infected with B. cenocepacia before transplant
were six times more likely to die within 1 year of trans-
plant than those infected with other Bcc species (p =
0.04) and eight times than noninfected patients (p <
0.00005). Following LT, infection with Bcc species other
than B. cenocepacia does not significantly impact 5-
year survival whereas infection with B. cenocepacia
pretransplant is associated with decreased survival.
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Introduction
The Burkholderia cepacia complex (Bcc) consists of at
least nine phenotypically similar but genotypically distinct
species (previously referred to as genomovars) of non-
fermenting, gram-negative rods. These include B. cepa-
cia (genomovar I), B. multivorans (genomovar II), B. ceno-
cepacia (genomovar III), B. stabilis (genomovar IV), B. viet-
namiensis (genomovar V), B. dolosa (genomovar VI), B.
ambifaria (genomovar VII), B. anthina (genomovar VIII) and
B. pyrrocinia (genomovar IX) (1–4). Colonization and sub-
sequent infection in cystic fibrosis (CF) patients with Bcc
has been associated with poor outcomes, including accel-
erated decline in pulmonary function and fatal disease (5–
7). Organisms belonging to each Bcc species have been
recovered from patients with CF; however, the majority of
clinical isolates are B. multivorans and B. cenocepacia (8–
11). Furthermore, isolates associated with increased mor-
bidity and mortality may cluster within the B. cenocepa-
cia species (12,13). Several epidemiologic studies have
shown that some strains of Bcc are highly transmissible be-
tween patients, although a few studies have shown no ev-
idence of transmission (14). Based on these observations,
it seems that certain Bcc species and / or strains may be
more transmissible than others, and likewise, some may
be more virulent.
Lung transplantation is a therapeutic option for an increas-
ing number of persons affected by CF. Patients with CF
who are infected with Bcc present a particular dilemma
for lung transplantation. Aris et al. reported in a retrospec-
tive review of patients undergoing lung transplantation that
mortality was significantly increased in patients infected
with Bcc (15). Snell and colleagues had previously reported
a similar finding of high mortality (47%) among patients in-
fected with Bcc prior to transplant (16). In a series of 53 CF
patients transplanted in Toronto between 1988 and 1996,
1-year survival was 67% in the Bcc-infected patients ver-
sus 92% among noninfected patients. A majority (9/15,
60%) of deaths in the Bcc cohort was in the first 3 months
following transplantation and was characterized by pro-
gressive acute respiratory distress syndrome and sepsis
(17). Consequently, many centers consider infection with
Bcc a contraindication to transplantation. Other centers,
however, continued to transplant these patients. In support
of this practice, Kanj et al. reported the early experience at
Duke University Medical Center (DUMC), where infection
with Burkholderia species did not seem to predict a worse
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outcome (18). Likewise, Flume and Egan reported lower
mortalities associated with Bcc infection than previously
described (19,20). More recent studies suggest that within
the Bcc, B. cenocepacia is associated with increased mor-
tality rates compared with other species (21–23). For ex-
ample, of 121 CF patients transplanted at the University of
North Carolina, excessive early mortality was noted in Bcc-
infected patients, with a 6-month mortality of 33% com-
pared with 12% in noninfected patients. All early deaths
occurred in patients infected with B. cenocepacia (22).
DUMC is a CF treatment and lung transplantation cen-
ter. The first lung transplant (LT) procedure at DUMC was
performed in 1992, and until 2002, patients infected with
Bcc including B. cenocepacia were regularly transplanted
at DUMC. This retrospective investigation was performed
to assess the impact of Bcc infection on mortality and re-
infection following lung transplantation in patients with CF.
Materials and Methods
Following Duke University Health System Institutional Review Board ap-
proval, the DUMC LT database was queried for all patients undergoing
transplantation between September 1992 and August 2002 and consec-
utive patients with CF as the underlying disease leading to LT were thus
identified and included in the study. Using a standardized case report form,
clinical data were collected from paper charts and computerized records.
Recipient age at time of transplant, donor age, mechanical ventilation for
recipient at time of LT, graft ischemia time, mismatches in human leukocyte
antigens, donor/recipient CMV serostatus and date of death and/or lung re-
transplantation were recorded. Complete 5 year follow-up was available on
each patient. Prior to transplant, respiratory samples were submitted for
bacterial culture that included Bcc selective media (OFPBL Agar, Remel,
Lenexa, KS), as part of routine work-up for transplantation and for manage-
ment of CF including acute exacerbations. Patients underwent surveillance
bronchoscopy with bronchoalveolar lavage (BAL) bacterial culture at 1, 3,
6, 9 and 12 months posttransplant or at any point if clinical indications de-
veloped (e.g. decrease in lung function, fever, new infiltrate on chest radio-
graph). Sputum samples for diagnostic purposes were also submitted from
patients with clinical symptoms who were able to produce sputum.
Bcc were defined as multidrug resistant if they were intermediate or resis-
tant to at least one agent in each of three classes of antibiotics including the
b-lactams, sulfonamides and fluoroquinolones. Organisms were defined as
panresistant if they were resistant to all drugs tested. LT recipients infected
with Bcc generally received four systemic antibiotics known to be effective
against the patient’s Bcc isolate based on susceptibility testing for at least
3 weeks. For isolates found to be multidrug or panresistant, antibiotics
were selected based on two-drug combination synergy testing performed
by Dr. Lisa Saiman’s laboratory, Columbia University. All CF patients trans-
planted at DUMC also received aerosolized colistin and tobramycin for 3
months following transplant as routine prophylaxis, regardless of infecting
flora. Patients received triple drug immunosuppression with cyclosporine
(prior to 1999) or tacrolimus (after 1999), azathioprine and corticosteroids.
Induction with an interleukin-2 receptor agent (basiliximab) was also admin-
istered beginning in 1999. Details of the surgical procedure, posttransplant
management and follow-up have been previously described (24,25).
The DUMC Clinical Microbiology Laboratory (CML) maintains a frozen sam-
ple (–70◦C) of all bacterial isolates obtained from blood as well as isolates
obtained from respiratory specimens of persons with CF. Gram-negative,
oxidase-positive, nonfermenting rods were preliminarily identified as Bcc by
cell wall analysis with gas-liquid chromotography (MIDI System; Microbial
ID, Newark, DE). The CML database was queried for all cultures submit-
ted from this cohort of patients to identify cultures that grew Bcc. Isolates
were categorized based on clinical specimen type and date of specimen
collection and those isolates available were recovered from frozen stocks
and further analyzed at the Burkholderia cepacia Research Laboratory and
Repository, University of Michigan. Isolates were confirmed as members
of the genus Burkholderia, and species designation within the Bcc was de-
termined utilizing 16S rDNA and recA species-specific polymerase chain
reaction (PCR) and recA restriction fragment length polymorphism (RFLP)
analyses (26,27). Box PCR typing was performed, as previously described,
on isolates to determine strain relatedness (28). For the purposes of this
study, distinct strain types were assigned different alphabetic designations.
Statistical method
Statistical analyses were performed using Analyse-It software (Analyse-
It Software Ltd, Leeds, UK) for Microsoft Excel and JMP Statistical Dis-
covery Program (version 6.0, SAS Institute, Cary, NC) and a type-I error
rate of 0.05. Descriptive statistics performed on the data set included
measures of central tendency and spread for continuous variables and
percentages and frequencies for categorical variables. Infection status
within 1 year prior to transplant was divided into three following cat-
egories for analysis purpose: patients without Bcc isolated were con-
sidered ‘noninfected’, patients harboring a species of Bcc other than
B. cenocepacia were considered ‘other Bcc species’ and patients har-
boring B. cenocepacia were considered ‘B. cenocepacia’. Subjects for
whom Bcc was isolated within 1 year of LT but for whom no isolate
was available for further speciation were excluded from analysis. Subjects
for whom Bcc was not isolated prior to transplant but was isolated af-
ter transplant were considered ‘noninfected’. Three way comparisons be-
tween the groups based on infection status were performed using one-
way ANOVA for continuous variables including the Kruskal-Wallis test for
nonparametric sensitivity analyses and Tukey’s method for multiple com-
parisons. The chi-square test was used for categorical variables. Survival
curves were calculated with the Kaplan–Meier method and compared us-
ing the log-rank test. Survival status was divided into two categories—‘alive’
or ‘dead or retransplanted’ at 1 year post LT. Logistic regression analyses
were performed to investigate the relationship of infection status, recipient
age at time of transplant, donor age, mechanical ventilation for recipient
at time of LT, graft ischemia time, mismatches in human leukocyte anti-
gens, receipt of trimethoprim/sulfamethoxazole following transplant and
donor/recipient CMV serostatus on survival status 1 year post LT. The sam-
ple size was insufficient for multivariable modeling. Missing data points
were not replaced.
Results
Seventy-six consecutive CF patients underwent LT at
DUMC between September 1992 and August 2002. During
the year before transplant, 59 (77.6%) patients were ‘non-
infected’, 9 (12.0%) harbored ‘other Bcc species’, includ-
ing B. multivorans (7 patients, 9.2%) and B. vietnamiensis
(2 patients, 2.6%), and 7 (9.2%) harbored B. cenocepacia.
One patient was excluded because her pretransplant iso-
late was not available for evaluation. Two patients had B.
cenocepacia isolated post transplant, including one patient
with both B. cenocepacia and B. multivorans, but no Bcc
isolated pretransplant. These patients were included in the
‘noninfected’ group for primary analysis. Four patients re-
quired a second transplant.
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Patient characteristics at the time of lung transplantation
are included in Table 1. The average patient age was 27.7
years (SD 8.5, range 11 to 53). Gender, CMV serostatus,
mean age at time of transplant, mean donor age, median
graft ischemic time and number of HLA mismatches did
not differ significantly between the three groups. All pa-
tients were Caucasian and only one, who was infected
with B. cenocepacia, was of Hispanic/Latino ethnicity. Six
(86%) patients had multidrug resistant B. cenocepacia, of
which three (43%) had panresistant B. cenocepacia. Seven
(78%) patients infected with ‘other Bcc species’ had mul-
tidrug resistant organisms recovered, of which five (56%)
were considered panresistant. Similarly, five (71%) and
seven (78%) patients in the B. cenocepacia and ‘other Bcc
species’ groups, respectively, were colonized with other
potential pathogens including Staphylococcus aureus or
another gram-negative rod. These differences were not
significant.
Of 16 CF patients infected with Bcc prior to transplant, all
but two had Bcc recovered from respiratory cultures post
transplant. These two patients had 9 and 4 BAL samples
cultured post transplant, respectively. All patients infected
with Bcc prior to transplant and who had Bcc recovered
from clinical specimens post transplant retained their pre-
transplant strains (Table 2).
Within 1 year of LT, 11 patients died including 8.5% (5/59) of
patients in the ‘noninfected’ group, 11.1% (1/9) of patients
in the ‘other Bcc species’ group and 71.4% (5/7) of patients
in the ‘B. cenocepacia’ group. Infection status was signifi-
cantly associated with 1-year survival (p < 0.0001). Survival
Table 1: Patient characteristics at the time of lung transplantation by pre-transplant Burkholderia cepacia complex (Bcc) infection status
Infection status1
B. cenocepacia Other Bcc species2 Noninfected
Variable N = 7 N = 9 N = 59
Recipient age in years 24 28 27
(Median, IQR) (21–33) (27–33) (22–33)
Male N (%) 3 (42.9) 4 (44.4) 26 (44.1)
Mechanical ventilation at time of transplant N (%) 0 0 6 (10.2)
CMV risk status3 N (%)
High 2 (28.6) 3 (33.3) 19 (32.2)
Intermediate 4 (57.1) 5 (55.6) 22 (37.3)
Low 1 (14.3) 1 (11.1) 18 (30.5)
Donor age in years 22 17 25
(Median, IQR) (17–28) (15–26) (15–40)
No. HLA mismatches 5 (4–5.5) 4 (4–5) 5 (4–5.25)
(Median, IQR)
Graft ischemic time (h) 634 652 636
(Median, IQR) (601.5–713.5) (525–706) (547.5–728.8)
1 infection status within 1 year prior to lung transplant.
2 Bcc species other than B. cenocepacia.
3 High risk, recipient seronegative and donor seropositive; Intermediate risk, seropositive recipient; Low risk, seronegative recipient and
donor.
SD = standard deviation; CMV = cytomegalovirus; HLA = human leukocyte antigens; IQR = interquartile range.
estimates for ‘noninfected’ patients were 97%, 92%, 76%
and 63%, at 1 month, 1 year, 3 years and 5 years, re-
spectively, compared with 89%, 89%, 67% and 56% in
patients with ‘other Bcc species’ and 71%, 29%, 29%
and 29% for patients with ‘B. cenocepacia’ (p = 0.0142,
Figure 1). Survival estimates were worse for patients with
‘B. cenocepacia’ when compared with all other patients
combined as a single group (p < 0.0037). In fact, patients
infected with B. cenocepacia prior to transplant were eight
times more likely to die within 1 year of transplant than
those not infected (RR = 8.43, 95% CI 3.23–22.03, p <
0.00005) and six times more likely to die within 1 year
of transplant than those infected with ‘other Bcc species’
prior to transplant (RR = 6.43, 95% CI, 0.95–43.26,
p = 0.04).
Gender, recipient age, donor age, mechanical ventilation
at time of transplant, graft ischemic time, mismatches
in human leukocyte antigens, CMV serostatus, receipt
of trimethoprim/sulfamethoxazole following transplant and
pre LT infection with ‘other Bcc species’ had no association
with 1-year survival.
Discussion
Several studies have established that for CF patients, in-
fection with Bcc is an independent predictor of early death
and accelerated decline in pulmonary function. Thus, many
patients infected with Bcc seek lung transplantation as
a life-extending option when their respiratory status be-
gins to decline. This investigation into the impact of Bcc
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Table 2: Burkholderia cepacia complex species and strain type infecting CF patients prior to and 5 years after lung transplantation
Strain type1
Burkholderia Survival
Patient species Pretransplant Posttransplant posttransplant (Days) Cause of death
1 B. cenocepacia AA AA 29 Burkholderia pneumonia
2 B. cenocepacia I No Bcc isolated 16 Anoxic brain injury
3 B. cenocepacia W W 170 Burkholderia sepsis
4 B. cenocepacia I I >1825 Alive
5 B. cenocepacia X No Bcc isolated 266 Respiratory failure/Rejection
6 B. cenocepacia AF AF >1825 Alive
7 B. cenocepacia S S 158 Burkholderia sepsis
8 B. cenocepacia No Bcc isolated B and A 223 Respiratory failure
B. multivorans C
9 B. cenocepacia No Bcc isolated B >1825 Alive
10 B. multivorans U U 1820 Burkholderia sepsis
11 B. multivorans AI AI 1086 Cancer
12 B. multivorans T T >1825 Alive
13 B. multivorans AJ AJ >1825 Alive
14 B. multivorans AH Bcc isolate not saved >1825 Alive
15 B. multivorans L L >1825 Alive
16 B. multivorans AC AC 1651 Bronchiolitis obliterans syndrome
17 B. vietnamiensis N N 26 Diffuse alveolar damage
18 B. vietnamiensis AB AB >1825 Alive
1 Each unique alphabet designation represents a distinct strain type, as determined by Box PCR typing.
respiratory infection in CF patients on re-infection rates and
survival following lung transplantation offers additional and
important insight for the management of these patients.
Contrary to the early data from our institution, infection
with Bcc prior to transplant, and more specifically, infection
with B. cenocepacia, significantly impacts survival. Mortal-
ity was significantly worse for those CF patients infected
with B. cenocepacia compared with noninfected CF pa-
tients and CF patients infected with Bcc species other than
B cenocepacia. Furthermore, the negative effect was most
dramatic during the first year following the transplant pro-
Figure 1: Five-year survival for
cystic fibrosis patients follow-
ing lung transplant based on
pretransplant Burkholderia cepa-
cia complex infection status. In-
fection status within 1 year prior
to transplant was divided into
three categories for analysis pur-
poses as follows: patients with-
out Bcc isolated were consid-
ered ‘noninfected’, patients harbor-
ing a species of Bcc other than
B. cenocepacia were considered
‘other Burkholderia species’ and
patients harboring B. cenocepacia
were considered ‘B. cenocepacia’.
cedure. Per Table 2, over half of the patients infected with
B. cenocepacia in our cohort were dead within the first 6
months following the transplant procedure, and Burkholde-
ria pneumonia or sepsis was considered the cause of death
for all but one. In contrast, Burkholderia infection was con-
sidered the cause of death for only one patient infected
with other Burkholderia species and as a contributor to the
cause of death for only one patient not infected with Bcc
prior to transplant (acquired following the transplant pro-
cedure), during the 5-year follow-up. Although this study
is clearly limited by the small number of patients with
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B. cenocepacia in the cohort and the retrospective de-
sign, the results are striking and are consistent with re-
ports from other LT centers (21,22). For example, De Soyza
and coworkers in Newcastle-Upon-Tyne, UK, reported early
deaths following lung transplantation for 4 of 4 patients
infected with B. cenocepacia strain ET12, which is com-
mon in eastern Canada and the UK and has been asso-
ciated with poor outcome (29), but no deaths among 5
patients infected with other Bcc species (mean follow-up
1.9 years) (21). Aris and colleagues at the University of
North Carolina reported the death of 5 of 12 patients in-
fected with B. cenocepacia (none of which were infected
with strain ET12) compared with no deaths in the 8 pa-
tients infected with other Bcc species (mean follow-up 1.5
years) (22). Our data confirm the early mortality associated
with B. cenocepacia infection and offer important new in-
sights into the long-term survival of patients infected with
other Bcc species. In fact, 5-year survival for patients in-
fected with Bcc other than B. cenocepacia did not signifi-
cantly differ from that of noninfected CF patients and ex-
ceeds that of other groups considered at high-risk follow-
ing lung transplantation, such as those transplanted due
to idiopathic pulmonary fibrosis or primary pulmonary hy-
pertension (www.ustransplant.org/annual reports/current/
survival rates.htm). As with the study by Aris et al., the het-
erogeneity of B. cenocepacia strains recovered in our co-
hort also indicates that increased virulence is not limited to
a single strain type (e.g. B. cenocepacia strain ET12). How-
ever, whether these observations can be extrapolated to
conclude that ‘all’ strains of B. cenocepacia have the same
capacity for poor outcome in LT recipients is not clear.
Consistent with previous reports from other institutions,
CF patients in our cohort were almost uniformly re-infected
with their pretransplant infecting strain of Bcc following
the LT procedure (14). All transplant recipients in this co-
hort received bilateral LTs, thereby eliminating a native lung
as a potential source of re-infection. All transplanted grafts
were cultured before implantation and none grew Bcc, ef-
fectively ruling out the transplanted lungs as the source
of infection. The sinuses are another potential and highly
likely reservoir for autologous infection of the new lungs.
Whether prophylactic sinus procedures in CF patients prior
to transplant would decrease the rate of pulmonary re-
infection would need to be studied. The majority of pa-
tients in our cohort did not undergo sinus surgery within
1 year prior to transplant; only one patient colonized with
‘B. cenocepacia’ and one patient colonized with ‘other Bcc
species’ underwent sinus surgery. Another important po-
tential source for re-infection is the patient’s caregivers; al-
though if this were the case, one would expect re-infection
with a strain different from their pretransplant clone in at
least some of the patients. With that said, our data do high-
light the importance of stringent infection control practices
to decrease nosocomial transmission of these pathogens.
Two of our patients had no B. cenocepacia recovered be-
fore transplantation, but did develop infection with B. ceno-
cepacia post transplant. One of these patients had B. ceno-
cepacia first recovered from BAL collected 70 days post
transplant although 5 total respiratory samples collected
throughout the year preceding transplant and the first 30
BALs collected post transplant did not grow a Bcc species.
Strain typing revealed this and subsequent B. cenocepa-
cia strains (B and A) recovered from this patient to be the
two strains identified during an outbreak of B. cenocepacia
bloodstream infections at our institution between August
1997 and April 2001 (13). This patient also had B. multi-
vorans recovered for the first time from BAL collected 85
days post transplant. Interestingly, this patient was never
discharged following transplant, resulting in a 7-month hos-
pitalization. The second patient had B. cenocepacia recov-
ered from respiratory samples 2 months following trans-
plant. Box PCR typing revealed this isolate to also be one
of the B. cenocepacia institutional outbreak strains (B).
Given the enhanced capacity for interpatient spread and
associated poor outcome, our center instituted strict in-
fection control measures, including gowning and gloving
upon entering the room of and handwashing after contact
with all Bcc-infected patients. The frequency of Bcc re-
covery within the institution rapidly decreased after these
interventions. Accordingly, in addition to adherence to rou-
tine infection control practices for all patients undergoing
lung transplantation, we strongly recommend placing any
patient infected with B cenocepacia under strict isolation
precautions (13).
Due to the excessive mortality seen among patients in-
fected with B. cenocepacia, the LT community is begin-
ning to re-consider lung transplantation as an option for
patients infected with this species. Available data support
screening of all CF patients for Bcc and excluding those
infected with B. cenocepacia from transplantation. Active
research continues regarding pathogenesis and epidemi-
ology of Bcc among CF patients. Currently, International
Society for Heart and Lung Transplantation guidelines do
not list B. cenocepacia infection as an absolute contraindi-
cation to lung transplantation; however, ‘colonization with
highly resistant or highly virulent bacteria’ is included as a
relative contraindication, thereby giving individual centers
the ability to dictate practice (30). As with other reports,
for CF patients infected with Bcc, antibiotic susceptibility
patterns were not helpful in determining the likelihood of
survival following lung transplantation (22). Although the
optimization of antibiotic combinations and attenuation of
immunosuppression for patients infected with Bcc have
been offered as means of improving survival for these pa-
tients following transplant (17), careful selection of a 4-
drug antibiotic regimen was not found to be beneficial in
our group of patients with B. cenocepacia. Similarly, treat-
ment with trimethoprim-sulfamethoxazole did not impact
outcomes. Furthermore, given the very high rates of acute
and chronic rejection after lung transplantation, it is unclear
if a strategy of reduced immunosuppression would lead to
any better long-term outcomes in this population due to the
potential for a corresponding increase in rejection related
deaths.
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Cooperation between CF treatment and LT centers will
hopefully provide new insights into virulence, transmissi-
bility and treatment regimens for this unique and challeng-
ing pathogen. More specifically, further studies to identify
which specific strains of B. cenocepacia may be more viru-
lent, the mechanisms behind the virulence in such strains
and investigations to tease out what host factors might in-
fluence progression of the infection in the CF population
should be a priority. Until then, we recommend the careful
screening of all CF patients for Bcc and excluding from LT
those harboring B. cenocepacia, regardless of susceptibil-
ity profile.
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